HepaLife's PBS-1 Cells for Influenza Vaccine Production Prove Superior at International Conference
BOSTON--(BUSINESS WIRE)--Jun 25, 2007 - HepaLife Technologies, Inc.(OTCBB: HPLF) (FWB: HL1) (WKN: 500625) today announced that newdata presented at an international influenza research conferencedemonstrates that HepaLife's patented PBS-1 cell line outperformscurrent cell technologies at replicating human influenza virusinside its cells. The most important step towards the production ofa cel...HepaLife Announces Scientific Presentation of PBS-1 Cell Line at International Influenza Meeting
BOSTON--(BUSINESS WIRE)--May 29, 2007 - HepaLife Technologies, Inc.(OTCBB:HPLF) (FWB:HL1) (WKN:500625) is pleased to announce ascientific presentation of its cell based PBS-1 technology forpotential influenza vaccine production at the "Options for theControl of Influenza VI Conference," to be held June 17-23, 2007,in Toronto, Canada. Entitled "High titer growth of human and avian influenz...